» Articles » PMID: 33869286

A Novel Defined Risk Signature of the Ferroptosis-Related Genes for Predicting the Prognosis of Ovarian Cancer

Overview
Specialty Biology
Date 2021 Apr 19
PMID 33869286
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Ferroptosis is an iron-dependent, regulated form of cell death, and the process is complex, consisting of a variety of metabolites and biological molecules. Ovarian cancer (OC) is a highly malignant gynecologic tumor with a poor survival rate. However, the predictive role of ferroptosis-related genes in ovarian cancer prognosis remains unknown. In this study, we demonstrated that the 57 ferroptosis-related genes were expressed differently between ovarian cancer and normal ovarian tissue, and based on these genes, all OC cases can be well divided into 2 subgroups by applying consensus clustering. We utilized the least absolute shrinkage and selection operator (LASSO) cox regression model to develop a multigene risk signature from the TCGA cohort and then validated it in an OC cohort from the GEO database. A 5-gene signature was built and reveals a favorable predictive efficacy in both TCGA and GEO cohort ( < 0.001 and = 0.03). The GO and KEGG analysis revealed that the differentially expressed genes (DEGs) between the low- and high-risk subgroup divided by our risk model were associated with tumor immunity, and lower immune status in the high-risk group was discovered. In conclusion, ferroptosis-related genes are vital factors predicting the prognosis of OC and could be a novel potential treatment target.

Citing Articles

Senescence-Related LncRNAs: Pioneering Indicators for Ovarian Cancer Outcomes.

Fan S, Xie X, Wei W, Hua T Phenomics. 2024; 4(4):379-393.

PMID: 39583315 PMC: 11584837. DOI: 10.1007/s43657-024-00163-z.


Explore the expression of mitochondria-related genes to construct prognostic risk model for ovarian cancer and validate it, so as to provide optimized treatment for ovarian cancer.

Yunyun Z, Guihu W, An J Front Immunol. 2024; 15:1458264.

PMID: 39478854 PMC: 11521951. DOI: 10.3389/fimmu.2024.1458264.


The recent advancements of ferroptosis of gynecological cancer.

Tang S, Chen L Cancer Cell Int. 2024; 24(1):351.

PMID: 39462352 PMC: 11520064. DOI: 10.1186/s12935-024-03537-5.


Novel protein-based prognostic signature linked to immunotherapeutic efficiency in ovarian cancer.

Chen S, Wang L, Lin Y, Chen C J Ovarian Res. 2024; 17(1):190.

PMID: 39342345 PMC: 11437962. DOI: 10.1186/s13048-024-01518-w.


Ferroptosis: mechanism, immunotherapy and role in ovarian cancer.

Guo K, Lu M, Bi J, Yao T, Gao J, Ren F Front Immunol. 2024; 15:1410018.

PMID: 39192972 PMC: 11347334. DOI: 10.3389/fimmu.2024.1410018.


References
1.
Huang Y, Dai Z, Barbacioru C, Sadee W . Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005; 65(16):7446-54. DOI: 10.1158/0008-5472.CAN-04-4267. View

2.
Conrad M, Kagan V, Bayir H, Pagnussat G, Head B, Traber M . Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev. 2018; 32(9-10):602-619. PMC: 6004068. DOI: 10.1101/gad.314674.118. View

3.
Lobello N, Biamonte F, Pisanu M, Faniello M, Jakopin Z, Chiarella E . Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition. Oncotarget. 2016; 7(38):62019-62033. PMC: 5308708. DOI: 10.18632/oncotarget.11495. View

4.
Koppula P, Zhuang L, Gan B . Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2020; 12(8):599-620. PMC: 8310547. DOI: 10.1007/s13238-020-00789-5. View

5.
Yang W, Stockwell B . Ferroptosis: Death by Lipid Peroxidation. Trends Cell Biol. 2015; 26(3):165-176. PMC: 4764384. DOI: 10.1016/j.tcb.2015.10.014. View